UGI Great Debate: Should we use FLOT or CROSS for Neoadjuvant Therapy for Patients with Resectable Gastro-esophageal Junction Adenocarcinomas?

Moderator(s)

• 

  Natalie Coburn, MD, MPH, FRCSC, FACS (she/her/hers)

  Director
  Evaluative Clinical Sciences, Sunnybrook Research Institute

  Disclosure(s): No financial relationships to disclose

Patients with resectable gastroesophageal junction (GEJ) adenocarcinomas are often treated with neoadjuvant therapy. Treatment options include the FLOT chemotherapy regimen and the CROSS chemoradiation regimen. However, there are no guidelines on how to prioritize one over the other. How do we decide which regimen to use for patients with GEJ adenocarcinomas?

Presentations:

• 9:45am – 10:00am ET

  FLOT should be used as the Neoadjuvant Regimen for Patients with Resectable GEJ
  

  Debater: Matthew R. Porembka, MD (he/him/his) – University of Texas Southwestern Medical Center
• 10:00am – 10:15am ET

  CROSS should be used as the Neoadjuvant Regimen for Patients with Resectable GEJ Adenocarcinomas
  

  Debater: Yanghee Woo, MD – Department of Surgical Oncology, City of Hope National Medical Center, Duarte, CA
• 10:15am – 10:30am ET

  Questions & Discussion